Literature DB >> 24018408

Dual RAS blockade-controversy resolved.

Piero Ruggenenti1, Giuseppe Remuzzi.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24018408     DOI： 10.1038/nrneph.2013.82-c2

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  13 in total

1.  Thrombotic microangiopathy: what not to learn from a meta-analysis.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

2.  Dual RAS blockade-unresolved controversy?

Authors:  Harikrishna Makani; Franz H Messerli; Sripal Bangalore; Kavit A Desouza; Arpit Shah; Johannes F E Mann
Journal:  Nat Rev Nephrol       Date:  2013-09-10       Impact factor: 28.314

3.  Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2013-04-30       Impact factor: 28.314

Review 4.  Proteinuria should be used as a surrogate in CKD.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-03-06       Impact factor: 28.314

5.  The Remission Clinic approach to halt the progression of kidney disease.

Authors: 
Journal:  J Nephrol       Date:  2011 May-Jun       Impact factor: 3.902

6.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

7.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

8.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

Authors:  Piero Ruggenenti; Annalisa Perna; Giuseppe Remuzzi
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

9.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 10.  Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.

Authors:  Harikrishna Makani; Sripal Bangalore; Kavit A Desouza; Arpit Shah; Franz H Messerli
Journal:  BMJ       Date:  2013-01-28
View more
  1 in total

Review 1.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.